preclinical studies
PhaSER secures $2.7m Gates Foundation renewal for neglected disease drug research
November 14, 2026Chagas disease, Chronic Diseases, Gates Foundation, Infections and infestations, Pharmacy, Rare Diseases, TB, malaria, neglected disease, preclinical studies
Scottish drug development company PhaSER Biomedical has secured a US$2.7m (£2m), two-year grant renewal from the Gates Foundation to support …
Latest content
Recruitment experts hired in search for new CGT Catapult chief
November 14, 2026
Envirogen secures place on NHS Scotland reverse osmosis framework
November 13, 2026
